

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 August 2011 (25.08.2011)

PCT

(10) International Publication Number
WO 2011/103202 A2

(51) International Patent Classification:

C07D 401/04 (2006.01) **A61K 31/5025** (2006.01)
C07D 487/04 (2006.01) **A61P 5/26** (2006.01)
A61K 31/4439 (2006.01) **A61P 5/28** (2006.01)

(21) International Application Number:

PCT/US2011/025106

(22) International Filing Date:

16 February 2011 (16.02.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/305,082 16 February 2010 (16.02.2010) US
61/329,023 28 April 2010 (28.04.2010) US
61/388,457 30 September 2010 (30.09.2010) US

(71) Applicant (for all designated States except US):
ARAGON PHARMACEUTICALS, INC. [US/US];
12780 El Camino Real, Suite 301, San Diego, CA 92130
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SMITH, Nicholas, D.** [US/US]; 1204 Beryl Street, San Diego, CA 92109 (US). **BONNEFOUS, Celine** [US/US]; 4425 Via Sepulveda, Unit #3, San Diego, CA 92122 (US). **JULIEN, Jackaline, D.** [US/US]; 517 1/2 Stratford Ct., Del Mar, CA 92014 (US).

(74) Agents: **HOSTETLER, Michael, J.** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: ANDROGEN RECEPTOR MODULATORS AND USES THEREOF

(57) Abstract: Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.



WO 2011/103202 A2